A Phase IIIb/IV comparative, randomised, multi-centre, open label, parallel 3-arm clinical study to assess the safety and efficacy of repeated administration of ACT therapy (pyronaridine-artesunate or dihydroartemisinin-piperaquine will be compared to either artesunate-amodiaquine or artemether-lumefantrine)

Trial Profile

A Phase IIIb/IV comparative, randomised, multi-centre, open label, parallel 3-arm clinical study to assess the safety and efficacy of repeated administration of ACT therapy (pyronaridine-artesunate or dihydroartemisinin-piperaquine will be compared to either artesunate-amodiaquine or artemether-lumefantrine)

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Artesunate/pyronaridine (Primary) ; Dihydroartemisinin/piperaquine (Primary)
  • Indications Malaria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms WANECAM-EDCTP
  • Most Recent Events

    • 20 Apr 2016 According to Medicines for Malaria Venture media release, following the EMA's initial positive scientific opinion in 2012, this trial was conducted by the West African Network for Antimalarial Drugs (WANECAM) from 2011-2016.
    • 27 Oct 2015 New trial record
    • 23 Oct 2015 Sub-study results published in The Lancet Infectious Diseases, as per Medicines for Malaria Venture media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top